Patents by Inventor Kyoichi Kaira

Kyoichi Kaira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy
    Patent number: 11899019
    Abstract: Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting a response of the subject to the anti-PD-1 antibody or anti-PD-L1 antibody therapy based on the expression level of LAT1. The method for evaluating a malignancy of cancer in a subject includes staining a sample collected from a cancer tissue of the subject with an anti-LAT1 antibody and an anti-PD-L1 antibody; and evaluating a malignancy of the cancer in the subject based on a presence or absence of a LAT1-positive and PD-L1-positive site.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: February 13, 2024
    Assignees: J-PHARMA CO., LTD., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Hitoshi Endou, Goshi Ishihara, Kyoichi Kaira, Yoshikatsu Kanai
  • METHOD FOR PREDICTING EFFICACY OF ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY THERAPY, METHOD FOR EVALUATING CANCER GRADE, AND METHOD FOR ENHANCING EFFICACY OF ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY THERAPY
    Publication number: 20210148920
    Abstract: Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting a response of the subject to the anti-PD-1 antibody or anti-PD-L1 antibody therapy based on the expression level of LAT1. The method for evaluating a malignancy of cancer in a subject includes staining a sample collected from a cancer tissue of the subject with an anti-LAT1 antibody and an anti-PD-L1 antibody; and evaluating a malignancy of the cancer in the subject based on a presence or absence of a LAT1-positive and PD-L1-positive site.
    Type: Application
    Filed: November 7, 2018
    Publication date: May 20, 2021
    Applicants: J-Pharma Co., Ltd., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Hitoshi Endou, Goshi Ishihara, Kyoichi Kaira, Yoshikatsu Kanai